ValuEngine Lowers Five Prime Therapeutics (FPRX) to Strong Sell
ValuEngine lowered shares of Five Prime Therapeutics (NASDAQ:FPRX) from a sell rating to a strong sell rating in a research report sent to investors on Wednesday.
FPRX has been the subject of several other research reports. Zacks Investment Research lowered shares of Five Prime Therapeutics from a hold rating to a sell rating in a research note on Wednesday, February 14th. BidaskClub upgraded shares of Five Prime Therapeutics from a sell rating to a hold rating in a research note on Thursday, December 21st. BMO Capital Markets lowered their target price on shares of Five Prime Therapeutics from $75.00 to $60.00 and set an outperform rating for the company in a research note on Wednesday, February 28th. Finally, Nomura reduced their price target on shares of Five Prime Therapeutics from $94.00 to $25.00 and set a buy rating for the company in a report on Wednesday, February 28th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The company currently has an average rating of Hold and a consensus price target of $47.20.
FPRX stock opened at $16.14 on Wednesday. Five Prime Therapeutics has a 1-year low of $15.66 and a 1-year high of $48.87.
Institutional investors and hedge funds have recently made changes to their positions in the company. Teacher Retirement System of Texas acquired a new position in shares of Five Prime Therapeutics during the fourth quarter valued at $221,000. MetLife Investment Advisors LLC acquired a new position in shares of Five Prime Therapeutics during the fourth quarter valued at $294,000. Virtus Fund Advisers LLC acquired a new position in shares of Five Prime Therapeutics during the fourth quarter valued at $381,000. Fox Run Management L.L.C. acquired a new position in shares of Five Prime Therapeutics during the fourth quarter valued at $386,000. Finally, Franklin Street Advisors Inc. NC acquired a new position in shares of Five Prime Therapeutics during the fourth quarter valued at $548,000. 74.34% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.thecerbatgem.com/2018/04/22/valuengine-lowers-five-prime-therapeutics-fprx-to-strong-sell.html.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.